Document text
Principal Investigator: SUBHRA MOHAPATRA
Organization: JAMES A. HALEY VA MEDICAL CENTER
Fiscal Year: 2021
Funding agency: Veterans Affairs
COVID-19 super pandemic is still suffering from the lack of a vaccine or infection control measures
and the lack of any treatments against this new virus. One of the unique features of SARS-CoV-2 is
that it has an R0=2.2 (the ability of an infected patient to spread the disease) vs R0=1 for SARS-CoV
and R0=0.3 for Influenza. Due to this, individuals infected with SARS-CoV-2 remain asymptomatic
and yet pass on the virus to family, friends and colleagues at work, thus expanding the COVID-19
cases. Given the impending second wave of the pandemic and the potential of SARS-CoV-2 being
a seasonal virus, there is a dire urgent need to develop prophylactic vaccines and/or therapy (PV/T),
which can treat the viral infection during the virus expansion in the lung and during oxygen therapy.
This proposal addresses the COVID-19 pandemic by developing a PV/T, which will be a unique
approach that has not been tested before. This project is inspired by discovery of a special agent,
i.e., a nanoscale 10 kDa chitosan, derived using proprietary methods from chitosan used as a
common diet supplement [‘generally regarded as safe’ (GRAS) by FDA]
, referred to as nanoscale
chitosan derivative (NCD). NCD1 and other chemical derivatives were synthesized and tested for
their anti-viral activity by neutralizing RNA of viruses, such as HIV, respiratory syncytial virus (RSV)
and Coxsackie virus. Thus, in preliminary studies, 5 out of 9 examined showed significant anti-viral
(80-90%) effects. Further, molecular docking studies showed that NCD1 can dock to the Spike
protein of SARS-CoV-2 virus. Finally, we have developed lung targeted nanomedicine methods to
combine NCD1 with remdesivir for improving treatment efficacy and expanding its use for prevention.
Based on data at hand, it is hypothesized that NCDs by themselves or in combination with remdesivir
will provide an excellent PV/T against COVID-19. To test this hypothesis, it is planned to examine in
both prophylactic and therapeutic settings: the antiviral effectiveness of NCDs in vitro lung epithelial
cell cultures (aim #1), the effectiveness of select top two NCDs with or without remdesivir in
EpiAlveolar 3D co-culture model (MatTek) of the air-blood barrier (aim #2), and efficacy of select
NCD with or without remdesivir in in vivo mouse models (aim #3).
The results will provide us in
identifying one or two NCDs as a single agent or in combination with remdesivir as COVID-19 PV/T
regimen(s), which will inhibit SARS-CoV-2 infection. The results of these studies will uniquely
contribute to the repertoire of COVID-19 prophylactics and therapeutics and allow us to move
towards regulatory approval and future clinical trials. The team is uniquely poised to conduct these
studies and has appropriate expertise. The successful completion of the proposed research is
expected to lead to obtaining regulatory approval for a clinical trial.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><3-D><3-Dimensional><3D><ACE2><AIDS Virus><ARDS><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Acute Respiratory Distress><Acute Respiratory Distress Syndrome><Address><Adult ARDS><Adult RDS><Adult Respiratory Distress Syndrome><Affect><Alveolocapillary Membrane><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Bioassay><Biologic Assays><Biological><Biological Assay><Blood-Air Barrier><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19><COVID-19 S protein><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19><COVID19 S protein><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 therapy><COVID19 treatment><COVID19 virus><CV-19><CV19><Cell Body><Cell Culture Techniques><Cell model><Cells><Cellular model><Cessation of life><Chemicals><Chitosan><Clinical Trials><Co-culture><CoV emergence><CoV-2><CoV2><Cocultivation><Coculture><Coculture Techniques><Combined Modality Therapy><Country><Coxsackie Viruses><Coxsackievirus><Da Nang Lung><Data><Death><Diagnosis><Disease><Disorder><Docking><Drugs><ELISA><Effectiveness><Endothelial Cells><Enzyme-Linked Immunosorbent Assay><Epithelial Cells><Evolution><FDA approved><Family><Fibroblasts><Friends><Future><GS-5734><Grippe><HIV><Hand><Human><Human Immunodeficiency Viruses><In Vitro><Individual><Infection><Infection Control><Influenza><LAV-HTLV-III><Lead><Lung><Lung Alveolar Epithelia><Lung Respiratory System><Lymphadenopathy-Associated Virus><Measures><Medication><Methods><Modeling><Modern Man><Molecular><Multimodal Therapy><Multimodal Treatment><O element><O2 element><Oxygen><Oxygen Inhalation Therapy><Oxygen Therapy Care><Patients><Pb element><Pharmaceutic Preparations><Pharmaceutical Preparations><Poliglusam><Preventative vaccine><Prevention><Preventive vaccine><Prophylactic treatment><Prophylactic vaccine><Prophylaxis><RNA Viruses><Regimen><Research><Respiratory syncytial virus><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Shock Lung><Stiff lung><Testing><Therapeutic><Toxic effect><Toxicities><Treatment Efficacy><Vaccines><Veklury><Viral><Viral Activity><Viral Burden><Viral Diseases><Viral Function><Viral Load><Viral Load result><Viral Physiology><Virus><Virus Diseases><Virus-HIV><Warburg Therapy><Work><Wuhan coronavirus><alveolar epithelium><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-viral agents><anti-viral drugs><anti-virals><base><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><cell culture><combination therapy><combined modality treatment><combined treatment><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus emergence><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus emergence><coronavirus patient><cross-link><crosslink><diet supplement><dietary supplements><drug/agent><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy testing><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><evaluate efficacy><examine efficacy><hCoV19><heavy metal Pb><heavy metal lead><immunocytochemistry><improved><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><innovate><innovation><innovative><intervention efficacy><mouse model><multi-modal therapy><multi-modal treatment><murine model><nCoV><nCoV2><nano medicinal><nano medicine><nano meter scale><nano meter sized><nano scale><nanomedicinal><nanomedicine><nanometer scale><nanometer sized><nanoscale><new CoV><new corona virus><new coronavirus><novel CoV><novel corona virus><novel coronavirus><novel virus><nutritional supplement><overexpress><overexpression><oxygen administration><oxygen therapy><pandemic><pandemic disease><particle><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><prophylactic><pulmonary><remdesivir><response><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome-CoV><therapeutic efficacy><therapy efficacy><three dimensional><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><triphosphate><tripolyphosphate><viral infection><virus infection><virus-induced disease><wet lung>